Summary
Amgen Inc.'s third quarter 2014 report shows mixed results for investors. While total revenues increased by 6% year-over-year to $5.03 billion, driven by strong performance in "Other revenues" and growth in key products like XGEVA® and Prolia®, net income declined by 9% to $1.24 billion. This decline is primarily attributable to a significant increase in operating expenses, notably cost of sales and restructuring charges, impacting profitability. The company has initiated a substantial restructuring plan, aiming to reduce its workforce and facility footprint, which resulted in $376 million in charges during the quarter. Despite these cost pressures and a decrease in earnings per share (EPS) to $1.61 from $1.79 in the prior year period, Amgen continues to return capital to shareholders through consistent dividend payments. The balance sheet remains robust, with total assets increasing to $70.8 billion, supported by substantial marketable securities and cash reserves.
Financial Highlights
55 data points| Revenue | $5.03B |
| Cost of Revenue | $1.07B |
| Gross Profit | $3.78B |
| SG&A Expenses | $1.21B |
| Operating Expenses | $3.56B |
| Operating Income | $1.47B |
| Interest Expense | $269.00M |
| Net Income | $1.24B |
| EPS (Basic) | $1.63 |
| EPS (Diluted) | $1.61 |
| Shares Outstanding (Basic) | 761.00M |
| Shares Outstanding (Diluted) | 771.00M |
Key Highlights
- 1Total revenues grew 6% year-over-year to $5.03 billion, primarily driven by a 14% increase in Rest of the World product sales and a significant 81% rise in Other Revenues.
- 2Net income decreased by 9% to $1.24 billion, and diluted EPS fell to $1.61 from $1.79, impacted by higher operating expenses.
- 3Operating expenses surged 17% to $3.57 billion, largely due to increased Cost of Sales (up 36%) and significant restructuring charges ($376 million recorded in Q3 2014).
- 4The company announced a significant restructuring plan involving workforce reductions (3,500-4,000 employees) and facility closures, with an estimated pre-tax charge of $935 million to $1.035 billion.
- 5Key products like XGEVA® (up 22%) and Prolia® (up 43%) showed strong sales growth, indicating continued market penetration and demand.
- 6Amgen maintained its dividend payments, declaring a quarterly cash dividend of $0.61 per share, and has $1.6 billion remaining under its stock repurchase program, with plans to reinitiate activity.
- 7The company's balance sheet remains strong with total assets of $70.8 billion and total cash, cash equivalents, and marketable securities at $28.1 billion.